Nonetheless, the progressive increase in CRISPLD1 expression during disease progression in AS patients points towards a functional role in the transition to HF, presumably as a negative regulator of Ca2+ cycling and thus, with the potential to augment CaT in the transition to HF to ameliorate cardiac contractility. Here, CRISPLD1 is linked to hydrops fetalis.